Lindsey Herrel

Assistant Professor

University of Michigan

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Lindsey Herrel is an Assistant Professor at the University of Michigan, USA. Her research focuses on urological cancers, gender equity in oncology, and the impact of social vulnerability on clinical trial participation. Recent publications examine topics including minimal residual disease using circulating tumour DNA, dual eligibility in oncology care, and the effects of private equity on urology practices.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Collaborators (1)

[email protected] Srivastava

University of Michigan

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Lindsey Herrel

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

A prospective study of minimal residual disease in urological cancers using circulating tumour DNA

Reply to “Promoting retention through belonging: A path to gender equity in oncologic specialties”

Gender equity in oncology: Progress, challenges, and the path forward in urologic oncology and oncologic specialties

Association of Community-Level Social Vulnerability With Clinical Trial Discussion and Participation Among Cancer Survivors

Quality of care for dual eligible beneficiaries in the oncology care model

The 340B Program and oral specialty drugs for advanced prostate cancer

Urologist practice divestment from radiation vault ownership and treatment patterns for prostate cancer

The immediate effects of private equity acquisition of urology practices on the management of newly diagnosed prostate cancer

Urologic oncology patient perspectives during COVID-19 treatment delays

Intensity of end‐of‐life care for dual‐eligible beneficiaries with cancer and the impact of delivery system affiliation

Collaborators (1)

[email protected] Srivastava

Make your next move.